Page last updated: 2024-11-04

ponalrestat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Ponalrestat is an aldose reductase inhibitor that is used to treat diabetic neuropathy. It works by blocking the enzyme aldose reductase, which is involved in the conversion of glucose to sorbitol. Sorbitol accumulation in nerve cells can lead to damage and neuropathy. Ponalrestat has been shown to reduce pain and improve nerve function in patients with diabetic neuropathy. It is a synthetic compound with the chemical name (S)-N-(3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-6-yl)-4-[2-(N-methyl-N-phenylamino)ethyl]benzene sulfonamide. It has been studied extensively for its potential therapeutic applications in treating diabetic neuropathy and other complications associated with diabetes. The importance of ponalrestat lies in its ability to target the underlying mechanism of diabetic neuropathy and offer a potential treatment for the associated pain and nerve damage. '

Cross-References

ID SourceID
PubMed CID5278
CHEMBL ID7679
CHEBI ID93199
SCHEMBL ID49154
MeSH IDM0126278

Synonyms (80)

Synonym
HMS3266J22
BRD-K68332390-001-03-3
BRD-K68332390-001-02-5
DIVK1C_006939
ici-128436
statil
prodiax
mk-538
ponalrestat
ponalrestat (usan/inn)
D03806
72702-95-5
SPECTRUM_001483
NCGC00024824-01
BIO1_000872
tocris-0847
BIO1_001361
BIO1_000383
BSPBIO_002576
c17h12brfn2o3
ponalrestatum [latin]
ici 128,436
1-phthalazineacetic acid, 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-
3-(4-bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic acid
KBIO3_001796
KBIO2_007099
KBIOGR_001855
KBIO2_001963
KBIO2_004531
KBIO1_001883
KBIOSS_001963
SPECTRUM4_001188
SPECPLUS_000843
SPECTRUM2_001467
SPECTRUM3_001048
SPBIO_001393
CHEMBL7679 ,
[3-(4-bromo-2-fluoro-benzyl)-4-oxo-3,4-dihydro-phthalazin-1-yl]-acetic acid(ponalrestat)
(ponalrestat)[3-(4-bromo-2-fluoro-benzyl)-4-oxo-3,4-dihydro-phthalazin-1-yl]-acetic acid
bdbm50009777
ponalrestat (statil)
[3-(4-bromo-2-fluoro-benzyl)-4-oxo-3,4-dihydro-phthalazin-1-yl]-acetic acid
2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxophthalazin-1-yl]acetic acid
NCGC00024824-02
2cv0a5g64e ,
ponalrestatum
unii-2cv0a5g64e
ponalrestat [usan:inn:ban]
tox21_110930
dtxsid1045665 ,
dtxcid9025665
cas-72702-95-5
1-phthalazineaceticacid, 3-[(4-bromo-2-fluorophenyl)methyl]-3,4-dihydro-4-oxo-
CCG-39192
ponalrestat [usan]
ponalrestat [inn]
ponalrestat [mart.]
SCHEMBL49154
smr004701478
MLS006010794
LKBFFDOJUKLQNY-UHFFFAOYSA-N
2-(2-fluoro-4-bromobenzyl)-1,2-dihydro-1-oxophthalazin-4-ylacetic acid
AKOS026750310
mfcd00204117
[3-(4-bromo-2-fluorobenzyl)-4-oxo-3h-phthalazin-1-yl]acetic acid (statil)
SR-01000597455-1
sr-01000597455
2-{3-[(4-bromo-2-fluorophenyl)methyl]-4-oxo-3,4-dihydrophthalazin-1-yl}acetic acid
CHEBI:93199
mk-538;statil
Q27164918
2-(3-(4-bromo-2-fluorobenzyl)-4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid
AS-35325
[3-(4-bromo-2-fluorobenzyl)-4-oxo-3h-phthalazin-1-yl]acetic acid
HY-106697
BCP13896
HMS3411P11
CS-0026367
A914009
1-phthalazineaceticacid,3-[(4-bromo-2-fluorophenyl)methyl]-3,4-dihydro-4-oxo-

Research Excerpts

Overview

Ponalrestat is a potent inhibitor (Ki = Kies = 7.7 nM) of ALR2 and follows a pure noncompetitive mechanism with respect to glucose.

ExcerptReferenceRelevance
"Ponalrestat is a potent inhibitor (Ki = Kies = 7.7 nM) of ALR2 and follows a pure noncompetitive mechanism with respect to glucose."( Ponalrestat: a potent and specific inhibitor of aldose reductase.
Dingle, A; Mirrlees, DJ; Ross, H; Sennitt, CM; Timms, D; Tuffin, DP; Ward, WH, 1990
)
2.44

Treatment

Ponalrestat treatment caused a decline which was mid-way between these two in standard medium and closer to that seen in control preparations in high glucose medium. Ponalrest at treatment completely prevented the characteristic nerve conduction slowing and structural abnormalities of the node of Ranvier for 4 mo.

ExcerptReferenceRelevance
"Ponalrestat treatment caused a decline which was mid-way between these two in standard medium and closer to that seen in control preparations in high glucose medium."( Increased resistance to hypoxic conduction block in sciatic nerves of diabetic rats: effects of extracellular glucose concentration and of aldose reductase inhibition.
Carrington, AL; Ettlinger, CB; Tomlinson, DR,
)
0.85
"Ponalrestat treatment reduced endoneurial fluid sodium and chloride concentrations by 25% and 37%, respectively (both P < 0.001)."( Decreased endoneurial fluid electrolytes in normal rat sciatic nerve after aldose reductase inhibition.
Calcutt, NA; Kalichman, MW; Mizisin, AP; Myers, RR; Powell, HC, 1993
)
1.01
"4. Ponalrestat treatment increased the resting and maximum tensions developed by cardiac tissues from diabetic animals and increased the maximum tensions developed by tissues from control animals."( Diabetes-induced changes in cardiac beta-adrenoceptor responsiveness: effects of aldose reductase inhibition with ponalrestat.
Austin, CE; Chess-Williams, R, 1991
)
1.01
"Ponalrestat treatment prevented both changes in the 30-day study but did not prevent a depression of responses to acetylcholine in the 6-month study."( Effects of diabetes on cholinergic transmission in two rat gut preparations.
Lucas, PD; Sardar, AM, 1991
)
1
"Ponalrestat treatment completely prevented the characteristic nerve conduction slowing and structural abnormalities of the node of Ranvier for 4 mo despite only partial preservation of axonal integrity."( Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
Chakrabarti, S; Greene, DA; Prashar, A; Sima, AA; Zhang, WX, 1990
)
1.24
"With ponalrestat treatment, the increase in contraction time was only 11%, and relaxation was only slowed by 4% (p less than 0.05 and p less than 0.01, respectively compared to diabetic controls)."( Contractile properties of cardiac papillary muscle in streptozotocin-diabetic rats and the effects of aldose reductase inhibition.
Cameron, NE; Cotter, MA; Robertson, S, 1989
)
0.73
"Ponalrestat treatment was started at day 3 after streptozotocin injection and was continued for the whole experimental period, i.e."( Impaired nerve regeneration in streptozotocin-diabetic rats. Effects of treatment with an aldose reductase inhibitor.
Ekström, AR; Tomlinson, DR, 1989
)
1
"Pretreatment with ponalrestat (25 mg kg-1, daily) prevented both the enhanced maximum contractile responses to phenylephrine and the depressed endothelium-dependent relaxations to carbachol in aortae from 14-day diabetic rats."( The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats.
Chess-Williams, R; Otter, DJ, 1994
)
0.87
"Treatment with Ponalrestat appeared to be safe and there were no side effects."( Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy.
Charbonnel, B; Feraille, E; Krempf, M; Ranganathan, S,
)
0.47
"Treatment with ponalrestat resulted in the attenuation of the decrease in the tissue weight."( Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor.
Inami, M; Kawamura, I; Manda, T; Naoe, Y; Sakai, F; Shimomura, K; Yamamoto, N; Yamazaki, H,
)
0.69

Toxicity

ExcerptReferenceRelevance
"Acrolein, a highly cytotoxic aldehyde, is a metabolic by-product of the antineoplastic agent cyclophosphamide and is responsible for the development of hemorrhagic cystitis, a serious side effect of cyclophosphamide therapy."( Aldose reductase-catalyzed reduction of acrolein: implications in cyclophosphamide toxicity.
Hunsaker, LA; Kolb, NS; Vander Jagt, DL, 1994
)
0.29

Bioavailability

ExcerptReferenceRelevance
" It was well absorbed in diabetic patients, resulting in high blood level, showed a highly favorable plasma half-life (27."( Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
Aldinger, CE; Beyer, TA; Dee, MF; Larson, ER; Mylari, BL; Siegel, TW; Singleton, DH; Zembrowski, WJ, 1991
)
0.28
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" (3) The dosing regimen of the second study was repeated and, at two sampling times, nine tissues and plasma were obtained from four rats per sampling time for determination of imirestat tissue-to-plasma concentration ratio."( Saturable tissue binding and imirestat pharmacokinetics in rats.
Banfield, CR; Brazzell, RK; Chien, JY; Mayer, PR; Slattery, JT, 1992
)
0.28
" Ponalrestat administration at a dosage of 600 mg daily for 12 months has no significant effect on the course of minimal retinopathy in diabetic patients."( The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy.
Barendsen, BC; Hooymans, JM; Tromp, A; van Doormaal, JJ, 1991
)
1.19
" Alternatively, the dosage used in the present study may not have been sufficient to achieve a complete prevention."( Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
Chakrabarti, S; Greene, DA; Prashar, A; Sima, AA; Zhang, WX, 1990
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phthalazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
TDP1 proteinHomo sapiens (human)Potency23.71500.000811.382244.6684AID686978
cytochrome P450 2C9 precursorHomo sapiens (human)Potency15.84890.00636.904339.8107AID883
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency15.84890.00638.235039.8107AID883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)0.61600.00041.877310.0000AID34961; AID34964; AID34975; AID95257
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)0.04800.00101.191310.0000AID309933; AID34201; AID34630
Aldo-keto reductase family 1 member B1Bos taurus (cattle)IC50 (µMol)0.02200.00702.589210.0000AID34207; AID34212
Aldo-keto reductase family 1 member A1Sus scrofa (pig)IC50 (µMol)2.00000.00051.66804.0000AID34179
Aldo-keto reductase family 1 member B1Sus scrofa (pig)IC50 (µMol)0.02100.01500.61352.5000AID34668
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
retinol metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID182492% inhibition of aldose reductase was measured in rat serbital sciatic nerves incubated in the presence of 50 mM glucose at 10e-6 M concentration1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID178210Effective dose of aldose reductase was evaluated by measuring galactitol accumulation in sciatic nerves of rat at 5 mg/kg/day1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID230205Inhibitory Activity ratio (IC50 ratio) calculated by Human recombinant aldose reductase wild type against Mutant Aldose reductase (W20Y)2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
AID230204Inhibitory Activity ratio (IC50 ratio) calculated by Human recombinant aldose reductase wild type against Mutant Aldose reductase (W20A).2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
AID182604In vivo inhibition of sorbitol accumulation in sciatic nerves from streptozotocin-diabetic rats dosed over 27 h. at a dose of 5 mg/kg1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.
AID182601In vivo inhibition of sorbitol accumulation in sciatic nerves from streptozotocin-diabetic rats dosed over 27 h. at a dose of 10 mg/kg1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.
AID34179Selectivity ratio measured as the IC50 ratio of aldehyde/aldose reductase values1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
AID176748Dose required for inhibition of sorbital accumulation in the sciatic nerve of streptozotocin- induced diabetic rat.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
AID309933Inhibition of aldose reductase2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.
AID230202Inhibitory Activity ratio (IC50 ratio) calculated by Human recombinant aldose reductase wild type against Mutant Aldose reductase (W111A)2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
AID179748In vitro inhibition of sorbitol accumulation was measured in rat sciatic nerves incubated in the presence of 50 mM glucose at 10e-5 M concentration1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID184011In vitro inhibition of sorbitol accumulation was measured in rat sciatic nerves incubated in the presence of 50 mM glucose at 10e-5 M concentration1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID182606In vivo inhibition of sorbitol accumulation in sciatic nerves from streptozotocin-diabetic rats dosed over 5 days. at a dose of 2.5 mg/kg1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.
AID179779In vivo inhibition of galactitol accumulation in sciatic nerves of rat at 5 mg/kg/day1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID232953Inhibitory activity measured against pig kidney aldehyde reductase using 3-pyridinecarboxaldehyde as substrate1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
AID232928Selectivity as ratio of IC50 for rat lens and kidney aldose reductase1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Spiro[fluoreneisothiazolidin]one dioxides: new aldose reductase and L-hexonate dehydrogenase inhibitors.
AID34975In vitro inhibition of Aldose reductase (AR) from rat lens (RL)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Spiro[fluoreneisothiazolidin]one dioxides: new aldose reductase and L-hexonate dehydrogenase inhibitors.
AID34201Inhibitory Activity against Human recombinant Aldose Reductase (wild type)2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
AID182731In vivo inhibition of sorbitol accumulation in sciatic nerves from streptozotocin-diabetic rats given three doses over 27 h. at a dose of 2.5 mg/kg1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.
AID34207Evaluated in vitro for the inhibition of Aldose reductase.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Synthesis, activity, and molecular modeling of new 2, 4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors.
AID34212In vitro Inhibition of aldose reductase was measured in isolated partially purified bovine lens preparations at 10e-7 M concentration1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID182390In vivo inhibition of galactitol accumulation in sciatic nerves of rat at 5 mg/kg/day1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID182081In vivo inhibition of galactitol accumulation in diaphragm of rat at 5 mg/kg/day1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID182607In vivo inhibition of sorbitol accumulation in sciatic nerves from streptozotocin-diabetic rats dosed over 5 days. at a dose of 25 mg/kg1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID34630Inhibition of aldose reductase (aldo-keto reductase, AKR1B1) isolated from human placenta.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
AID230203Inhibitory Activity ratio (IC50 ratio) calculated by Human recombinant aldose reductase wild type against Mutant Aldose reductase (W111Y).2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
AID34961Inhibitory activity against purified rat lens aldose reductase (RLAR)1994Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6
Molecular modeling studies of aldose reductase inhibitors.
AID182603In vivo inhibition of sorbitol accumulation in sciatic nerves from streptozotocin-diabetic rats dosed over 27 h. at a dose of 25 mg/kg1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.
AID34964Inhibitory activity measured against rat lens aldose reductase using 3-pyridinecarboxaldehyde as substrate1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
AID179749In vitro inhibition of sorbitol accumulation was measured in rat sciatic nerves incubated in the presence of 50 mM glucose at 10e-6 M concentration1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID95257In vitro inhibitory activity against L-Hexonate Dehydrogenase (L-HDH) from rat kidney (RK)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Spiro[fluoreneisothiazolidin]one dioxides: new aldose reductase and L-hexonate dehydrogenase inhibitors.
AID182605In vivo inhibition of sorbitol accumulation in sciatic nerves from streptozotocin-diabetic rats dosed over 5 days. at a dose of 10 mg/kg1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.
AID34668In vitro inhibitory activity against aldose reductase in porcine lens.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
AID182608In vivo inhibition of sorbitol accumulation in sciatic nerves from streptozotocin-diabetic rats dosed over 5 days. at a dose of 5 mg/kg1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (147)

TimeframeStudies, This Drug (%)All Drugs %
pre-199043 (29.25)18.7374
1990's85 (57.82)18.2507
2000's7 (4.76)29.6817
2010's9 (6.12)24.3611
2020's3 (2.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.96 (24.57)
Research Supply Index5.24 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials23 (13.94%)5.53%
Reviews11 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other131 (79.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]